Innovative and accredited continuing medical education for today’s practicing clinicians.
CME Institute is trusted by physicians across medical specialties for premium continuing education that yields the highest educational outcomes. These ACCME-accredited activities make the latest research, novel therapies, and clinical best practices accessible and approachable for physician, NP, PA, and PharmD learners.
- Expert-led insights to improve patient outcomes
- Multi-modal courses to suit all learning styles
- Timely topics for relevant application to practice
- Razor-focused approach to innovation that includes documentary-style video and micro-learning Tweetorials
- A commitment to collective mindfulness
Recent courses
Experts discuss appropriate treatment sequencing for patients with schizophrenia, including early use of LAIs and switching from an oral antipsychotic.
|
Experts compare data on hospitalization, adherence, relapse risk, tolerance and efficacy between LAIs and OAs in the treatment of schizophrenia.
|
An updated review of pathophysiology, emerging treatments, and supportive care strategies in the cognitive dimension of Huntington disease.
|
In treating agitation in bipolar disorder/schizophrenia in the emergency department, consider efficacy and safety of therapies as well as the safety of patient and staff.
|
Management for Parkinson's disease psychosis (PDP) includes evaluating triggers, non-Parkinson's drugs, Parkinson's drugs that may contribute to symptoms, behavioral interventions, and multidisciplinary collaboration between health providers.
|
Parkinson’s disease psychosis (PDP) is a nonmotor symptom of Parkinson’s disease (PD) and includes at least 1 symptom of hallucinations, illusions, delusions, or false sense of presence after onset of PD and recurrent/continuous for 1 month or more.
|
LAI antipsychotics are often initiated late in adults with schizophrenia, despite evidence supporting early use. Experts discuss the barriers to initiating LAI treatment, as well as adherence, efficacy and safety data.
|
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
|
Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.
|
Treatment standards for neurologists and other clinicians caring for patients with epilepsy with emphasis on understanding epilepsy epidemiology, SUDEP and ILAE Classification updates, and therapeutic strategies.
|
Neurologists and other clinicians can improve care by identifying individuals who are susceptible to seizure clusters and educating them on rescue therapies and medications.
|
Experts examine a patient case study as a way of translating guideline-based screening recommendations and current therapies that protect T2D patients from CKD progression in real-world practice.
|
Pages
My Courses
Please login or create an account to view your activities.
Transcript
Please login or create an account to view your activities.